284 related articles for article (PubMed ID: 35199647)
21. An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications.
Karanam NK; Story MD
Int J Radiat Biol; 2021; 97(8):1044-1054. PubMed ID: 33086019
[TBL] [Abstract][Full Text] [Related]
22. Baculovirus Transduction in Mammalian Cells Is Affected by the Production of Type I and III Interferons, Which Is Mediated Mainly by the cGAS-STING Pathway.
Amalfi S; Molina GN; Bevacqua RJ; López MG; Taboga O; Alfonso V
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796076
[TBL] [Abstract][Full Text] [Related]
23. Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma.
Xu S; Luo C; Chen D; Tang L; Chen L; Liu Z
Cell Death Dis; 2022 Aug; 13(8):721. PubMed ID: 35982032
[TBL] [Abstract][Full Text] [Related]
24. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
[TBL] [Abstract][Full Text] [Related]
25. cGAS deficiency enhances inflammasome activation in macrophages and inflammatory pathology in pristane-induced lupus.
Kumpunya S; Thim-Uam A; Thumarat C; Leelahavanichkul A; Kalpongnukul N; Chantaravisoot N; Pisitkun T; Pisitkun P
Front Immunol; 2022; 13():1010764. PubMed ID: 36591278
[TBL] [Abstract][Full Text] [Related]
26. Treatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma.
Sarkari A; Korenfeld S; Deniz K; Ladner K; Wong P; Padmanabhan S; Vogel RI; Sherer LA; Courtemanche N; Steer C; Wainer-Katsir K; Lou E
Elife; 2023 Nov; 12():. PubMed ID: 37955637
[TBL] [Abstract][Full Text] [Related]
27. Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy.
Pohling C; Nguyen H; Chang E; Schubert KE; Nie Y; Bashkirov V; Yamamoto V; Zeng Y; Stupp R; Schulte RW; Patel CB
Bioelectrochemistry; 2023 Feb; 149():108287. PubMed ID: 36306728
[TBL] [Abstract][Full Text] [Related]
28. Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation.
Qin Y; Pan L; Qin T; Ruan H; Zhang Y; Zhang Y; Li J; Yang J; Li W
Front Immunol; 2022; 13():998266. PubMed ID: 36248785
[TBL] [Abstract][Full Text] [Related]
29. The cyclic guanosine monophosphate synthase-stimulator of interferon genes pathway as a potential target for tumor immunotherapy.
Chen R; Liu M; Jiang Q; Meng X; Wei J
Front Immunol; 2023; 14():1121603. PubMed ID: 37153627
[TBL] [Abstract][Full Text] [Related]
30. Tumor-Treating Fields in Glioblastomas: Past, Present, and Future.
Guo X; Yang X; Wu J; Yang H; Li Y; Li J; Liu Q; Wu C; Xing H; Liu P; Wang Y; Hu C; Ma W
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954334
[TBL] [Abstract][Full Text] [Related]
31. Tumor treating fields: narrative review of a promising treatment modality for cancer.
Kutuk T; Atak E; La Rosa A; Kotecha R; Mehta MP; Chuong MD
Chin Clin Oncol; 2023 Dec; 12(6):64. PubMed ID: 37953242
[TBL] [Abstract][Full Text] [Related]
32. A General Biomineralization Strategy to Synthesize Autologous Cancer Vaccines with cGAS-STING Activating Capacity for Postsurgical Immunotherapy.
Li Q; Dong Z; Cao Z; Lei H; Wang C; Hao Y; Feng L; Liu Z
ACS Nano; 2023 Jun; 17(11):10496-10510. PubMed ID: 37184402
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Compatibility of Electric Tumor Treating Fields with Key Anti-tumoral T-Cell Functions.
Simchony H; Diamant D; Ram Z; Volovitz I
Isr Med Assoc J; 2019 Jul; 21(7):503. PubMed ID: 31507132
[TBL] [Abstract][Full Text] [Related]
34. The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy.
Tanzhu G; Chen L; Xiao G; Shi W; Peng H; Chen D; Zhou R
Cell Death Discov; 2022 Oct; 8(1):416. PubMed ID: 36220835
[TBL] [Abstract][Full Text] [Related]
35. Tumor treating fields: a new standard treatment for glioblastoma?
Taillibert S; Le Rhun E; Chamberlain MC
Curr Opin Neurol; 2015 Dec; 28(6):659-64. PubMed ID: 26551239
[TBL] [Abstract][Full Text] [Related]
36. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
Fishman H; Monin R; Dor-On E; Kinzel A; Haber A; Giladi M; Weinberg U; Palti Y
J Neurooncol; 2023 May; 163(1):83-94. PubMed ID: 37131108
[TBL] [Abstract][Full Text] [Related]
37. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB
Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495
[TBL] [Abstract][Full Text] [Related]
38. Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.
Wang Y; Pandey M; Ballo MT
Oncologist; 2019 Dec; 24(12):e1426-e1436. PubMed ID: 31444292
[TBL] [Abstract][Full Text] [Related]
39. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
40. cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy.
Long ZJ; Wang JD; Xu JQ; Lei XX; Liu Q
Mol Ther; 2022 Mar; 30(3):1006-1017. PubMed ID: 35121107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
